Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human PCSK9 Protein, His Tag, 50µg  

Recombinant human PCSK9 Protein, His Tag, 50µg

Recombinant human PCSK9(rhPCSK9) Gln31-Gln692, produced in human HEK293 cells, His Tag (MALS Verified)

Synonym
recombinant human protein, PCSK9, FH3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9, Proprotein convertase subtilisin/kexin type 9

More details

PC9-H5223-050

Availability: within 7 days

420,00 €

Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene.This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons.(1) Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).(2,3).

Source
Recombinant Human PCSK9, His Tag (PC9-H5223) is expressed from human 293 cells (HEK293). It contains AA Gln 31 - Gln 692 (Accession # Q8NBP7-1).
Predicted N-terminus: Gln 31 & Ser 153

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 59.2 kDa respectively. The protein migrates as 17 kDa and 65-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "STATINS, BUT NOT PCSK9 INHIBITORS, REDUCE THE ADIPOKINE CHEMERIN IN FAMILIAL HYPERCHOLESTEROLEMIA: FOCUS ON LIPOPROTEIN SUBFRACTIONS"
Tan, Wang, Van Vark Van Der Zee et al
J Hypertens (2022) 40 (Suppl 1), e299-e300
(2) "ACHIEVING THERAPEUTIC GOAL ON LDL IN HIGH AND VERY HIGH RISK PATIENTS IN A DEDICATED OUTPATIENT CLINIC"
Trenta, Napolitano, Maretta et al
J Hypertens (2022) 40 (Suppl 1), e126
(3) "[Lipid lowering: new agents and new concepts]"
Brandts, Verket, Müller-Wieland
Herz (2022)
Showing 1-3 of 4807 papers.

Citations
(1) "Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling"
Authors: Yuan J, Cai T, Zheng X, et al.
Journal: Protein Cell 2021
Application: Flow cytometry
(2) "The hepatic WASH complex is required for efficient plasma LDL and HDL cholesterol clearance"
Authors: M Wijers, et al
Journal: JCI Insight 2019
Application: Tissue culture
(3) "Side chain determinants of biopolymer function during selection and replication"
Authors: Lichtor PA, et al
Journal: Nat Chem Biol 2019
Application: SPR
Showing 1-3 of 10 papers.